NIO stock jumps as investors refocus on software, charging network and the next delivery update
29 January 2026
1 min read

NIO stock jumps as investors refocus on software, charging network and the next delivery update

New York, Jan 29, 2026, 11:35 AM EST — Regular session

  • NIO shares climbed roughly 3.6% in late morning trading, bouncing back after a sluggish finish the day before. 1
  • China’s EV maker announced a new over-the-air software update and shared new milestones for its battery swap network. 2
  • Traders are focusing on the upcoming monthly delivery report and hoping for a firmer date on the next earnings release. 3

NIO’s U.S.-listed shares gained on Thursday, continuing the volatile streak seen in Chinese EV stocks as investors digested near-term execution cues ahead of upcoming demand data.

The stock climbed roughly 3.6% to $4.76 in late morning trading, bouncing back from a 1.1% drop that closed Wednesday at $4.59. 1

This matters since NIO’s share price sits in the low single digits, where even minor shifts in sentiment can jolt the stock. Investors are hunting for clear evidence that product rollout and services revenue will help stabilize margins amid the fierce competition in China’s EV market. 4

Over the last two days, NIO highlighted advances in its software and services, announcing plans to start deploying the Banyan 3.3.0 system update on Jan. 28, according to a company post referenced by CnEVPost. 2

Founder and CEO William Li pointed to NIO’s growing charging and battery swapping network, revealing the company has completed nearly 99 million battery swaps as of Jan. 27, according to Gasgoo. (Battery swapping allows drivers to quickly exchange a drained battery for a fully charged one.) 5

NIO’s latest operating updates come as the company pushes its “battery-as-a-service” model and software advantages to stand out. It’s locked in a battle on pricing and refresh cycles with domestic rivals like XPeng and Li Auto. 4

That said, demand and pricing trends in China’s EV sector may get tougher to gauge come February. Any hint of discounting or a slowdown in orders could wipe out recent gains fast, especially given how reactive the stock has been to news. 4

Investors are zeroing in on delivery figures for a quick read on performance: NIO reported earlier in the month that December deliveries hit a record high, along with a quarterly record for Q4, signaling strong momentum as 2026 approaches. 3

The market’s focus now shifts to NIO’s January delivery figures, usually out in the opening days of the month. Investors are also gearing up for the Q4 earnings report, slated for mid-March according to event calendars. 3

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Nu Holdings stock slides even as Brazil tees up rate cuts — what investors are watching next
Previous Story

Nu Holdings stock slides even as Brazil tees up rate cuts — what investors are watching next

GE Vernova stock drops as Vineyard Wind delays muddy fresh 2026 outlook
Next Story

GE Vernova stock drops as Vineyard Wind delays muddy fresh 2026 outlook

Go toTop